Oral presented at ASH 2022 describing the potential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with either a BCL2 inhibitor alone or a BCL2 inhibitor in combination with a BTK inhibitor.

A summary of the latest developments from 12 studies in the treatment of NSCLC, gastric cancers and other solid tumors presented at ESMO 2022.

Report on updates in the treatment of lung and gastrointestinal cancers presented at ESMO 2021.

Report on recent developments in the treatment of B-cell malignancies presented at ASCO, EHA and ICML 2021.

Presentation from ASH 2021 describing emergent therapeutic options in BTKi-intolerant patients with relapsed/refractory (R/R) B-cell malignancies.